Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications

American Heart Journal

Volumn 168, Issue 5, 2014, Pages 632-644

  Camm, John ^a   Hla, Timothy ^b   Bakshi, Rajesh ^c   Brinkmann, Volker ^c  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; SPHINGOSINE 1 PHOSPHATE; IMMUNOSUPPRESSIVE AGENT; PROPANEDIOL DERIVATIVE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ARTICLE; ATRIOVENTRICULAR CONDUCTION; BLOOD PRESSURE; BLOOD VESSEL PERMEABILITY; BRADYCARDIA; CARDIOVASCULAR EFFECT; CARDIOVASCULAR PARAMETERS; CELL JUNCTION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; HEART MUSCLE CELL; HEART MUSCLE EXCITABILITY; HEART RATE; HEART RATE TURBULENCE; HUMAN; LONG TERM CARE; NONHUMAN; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); QT INTERVAL; QT PROLONGATION; SIGNAL TRANSDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR SYSTEM; DRUG EFFECTS; HEART ATRIOVENTRICULAR NODE; MULTIPLE SCLEROSIS;

ATRIOVENTRICULAR NODE; CARDIOVASCULAR SYSTEM; DOWN-REGULATION; HEART RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84908323531     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.06.028     Document Type: Review

References (94)

1. V. Brinkmann, M.D. Davis, and C.E. Heise The immune modulator FTY720 targets sphingosine 1-phosphate receptors J Biol Chem 277 2002 21453 21457
2. S. Mandala, R. Hajdu, and J. Bergstrom Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists Science 296 2002 346 349
3. European Medicines Agency Annex I. Summary of product characteristics. Gilenya (fingolimod) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002202/WC500104528.pdf 2011 [Accessed December 4, 2013]
4. US Food and Drug Administration Gilenya prescribing information http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022527s008lbl.pdf 2012 [Accessed December 4, 2013]
5. V. Brinkmann, A. Billich, and T. Baumruker Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Nat Rev Drug Discov 9 2010 883 897
6. L. Kappos, E.W. Radue, and P. O'Connor A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
7. J.A. Cohen, F. Barkhof, and G. Comi Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
8. P.A. Calabresi, E.W. Radue, and D. Goodin Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Neurol 13 2014 545 556
9. P. Chin, P. Calabresi, and Y. Zhang Early effect of fingolimod on clinical and MRI related outcomes in relapsing multiple sclerosis Mult Scler 18 4 Suppl. 2012 459
10. J.A. Cohen, E.W. Radue, and F. Barkhof Fingolimod-effect on brain atrophy and clinical/MRI correlations in three phase 3 studies - TRANSFORMS, FREEDOMS and FREEDOMS II Neurology 80 2013 [(Meeting Abstracts 1): S51.006]
11. V. Brinkmann FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system Br J Pharmacol 158 2009 1173 1182
12. M. Matloubian, C.G. Lo, and G. Cinamon Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 Nature 427 2004 355 360
13. 1) modulation Proc Natl Acad Sci U S A 108 2011 751 756
14. M. Rausch, P. Hiestand, and C.A. Foster Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging J Magn Reson Imaging 20 2004 16 24
15. J. Chun, and H.P. Hartung Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin Neuropharmacol 33 2010 91 101
16. C.A. Foster, L.M. Howard, and A. Schweitzer Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis J Pharmacol Exp Ther 323 2007 469 475
17. G. Tamagnan, A. Tavares, and O. Barret Brain distribution of BZM055, an analog of fingolimod (FTY720), in humans Mult Scler 18 4 Suppl. 2012 839
18. A. Groves, Y. Kihara, and J. Chun Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy J Neurol Sci 328 2013 9 18
19. V.A. Blaho, and T. Hla Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors Chem Rev 111 2011 6299 6320
20. V. Brinkmann Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology Pharmacol Ther 115 2007 84 105
21. C.K. Means, and J.H. Brown Sphingosine-1-phosphate receptor signalling in the heart Cardiovasc Res 82 2009 193 200
22. J.S. Karliner Lysophospholipids and the cardiovascular system Biochim Biophys Acta 1582 2002 216 221
23. 3, respectively, regulate lymphocyte recirculation and heart rate J Biol Chem 279 2004 13839 13848
24. K. Budde, R.L. Scmouder, and B. Nashan Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients Am J Transplant 3 2003 846 854
25. S. Spiegel, and S. Milstien Sphingosine-1-phosphate: an enigmatic signalling lipid Nat Rev Mol Cell Biol 4 2003 397 407
26. T.H. Pham, P. Baluk, and Y. Xu Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning J Exp Med 207 2010 17 27
27. 5 inhibits oligodendrocyte progenitor migration FASEB J 21 2007 1503 1514
28. J. Harada, M. Foley, and M.A. Moskowitz Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells J Neurochem 88 2004 1026 1039
29. R.R. Poulsen, C.M. McClaskey, and S.A. Rivkees The sphingosine-1-phospate receptor 1 mediates S1P action during cardiac development BMC Dev Biol 11 2011 37
30. K. Mendelson, T. Zygmunt, and J. Torres-Vazquez Sphingosine 1-phosphate receptor signaling regulates proper embryonic vascular patterning J Biol Chem 288 2013 2143 2156
31. M. Xu, C.L. Waters, and C. Hu Sphingosine 1-phosphate rapidly increases endothelial barrier function independently of VE-cadherin but requires cell spreading and Rho kinase Am J Physiol Cell Physiol 293 2007 C1309 C1318
32. 2 receptor subtype Cardiovasc Res 82 2009 221 228
33. J.F. Lee, S. Gordon, and R. Estrada Balance of S1P1 and S1P2 signaling regulates peripheral microvascular permeability in rat cremaster muscle vasculature Am J Physiol Heart Circ Physiol 296 2009 H33 H42
34. 2 J Neurosci 27 2007 1474 1478
35. P.A. Singleton, L. Moreno-Vinasco, and S. Sammani Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation Am J Respir Cell Mol Biol 37 2007 222 231
36. M. Graeler, and E.J. Goetzl Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells FASEB J 16 2002 1874 1878
37. 4) deficiency profoundly affects dendritic cell function and TH17-cell differentiation in a murine model FASEB J 25 2011 4024 4036
38. 4 receptor mediates S1P-induced vasoconstriction in normotensive and hypertensive rat lungs Pulm Circ 1 2011 399 404
39. C. Jaillard, S. Harrison, and B. Stankoff Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival J Neurosci 25 2005 1459 1469
40. K. Mayol, V. Biajoux, and J. Marvel Sequential desensitization of CXCR4 and S1P5 controls natural killer cell trafficking Blood 118 2011 4863 4871
41. I. Ishii, N. Fukushima, and X. Ye Lysophospholipid receptors: signaling and biology Ann Rev Biochem 73 2004 321 354
42. A. Billich, F. Bornancin, and P. Dévay Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases J Biol Chem 278 2003 47408 47415
43. T. Sanchez, T. Estrada-Hernandez, and J.H. Paik Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability J Biol Chem 278 2003 47281 47290
44. M. Uehata, T. Ishizaki, and H. Satoh Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension Nature 389 1997 990 994
45. M. Tölle, B. Levkau, and P. Keul Immunomodulator FTY720 induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3 Circ Res 96 2005 913 920
46. L. Koyrakh, M.I. Roman, and V. Brinkmann The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I Am J Transplant 5 2005 529 536
47. J. Igarashi, and T. Michel S1P and eNOS regulation Biochim Biophys Acta 1781 2008 489 495
48. B.J. McVerry, and J.G. Garcia Endothelial cell barrier regulation by sphingosine 1-phosphate J Cell Biochem 92 2004 1075 1085
49. S. Salomone, E.M. Potts, and S. Tyndall Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools Br J Pharmacol 153 2008 140 147
50. M.L. Oo, S. Thangada, and M.T. Wu Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor agonists induce ubiquitinylation and proteasomal degradation of the receptor J Biol Chem 282 2007 9082 9089
51. 1 receptor internalisation Br J Pharmacol 2014 10.1111/bph.12620
52. D. Pelletier, and D.A. Hafler Fingolimod for multiple sclerosis N Engl J Med 366 2012 339 347
53. H. Noda, H. Takeuchi, and T. Mizuno Fingolimod phosphate promotes the neuroprotective effects of microglia J Neuroimmunol 256 2013 13 18
54. V. Brinkmann, and T. Baumruker Pulmonary and vascular pharmacology of sphingosine 1-phosphate Curr Opin Pharmacol 6 2006 244 250
55. M. Forrest, S.Y. Sun, and R. Hajdu Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes J Pharmacol Exp Ther 309 2004 758 768
56. A.P. Dantas, J. Igarashi, and T. Michel Sphingosine 1-phosphate and control of vascular tone Am J Physiol Heart Circ Physiol 284 2003 H2045 H2052
57. 3 J Clin Invest 113 2004 569 581
58. M. Morales-Ruiz, M.J. Lee, and S. Zollner Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells J Biol Chem 276 2001 19672 19677
59. T.A. Taha, K.M. Argraves, and L.M. Obeid Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy Biochim Biophys Acta 1682 2004 48 55
60. M. Osinde, F. Mullershausen, and K.K. Dev Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors Neuropharmacology 52 2007 1210 1218
61. F. Coussin, R.H. Scott, and A. Wise Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction Circ Res 91 2002 151 157
62. 3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate Eur J Pharmacol 469 2003 125 134
63. D.G. Hemmings, Y. Xu, and S.T. Davidge Sphingosine 1-phosphate-induced vasoconstriction is elevated in mesenteric resistance arteries from aged female rats Br J Pharmacol 143 2004 276 284
64. C. Waeber, N. Blondeau, and S. Salomone Vascular sphingosine-1-phosphate S1P1 and S1P3 receptors Drug News Perspect 17 2004 365 382
65. 2 Am J Physiol Cell Physiol 286 2004 C1130 C1138
66. K.R. Watterson, P.H. Ratz, and S. Spiegel The role of sphingosine-1-phosphate in smooth muscle contraction Cell Signal 17 2005 289 298
67. 2 receptor function in smooth muscle by receptor silencing and receptor protection Am J Physiol Gastrointest Liver Physiol 291 2006 G605 G610
68. H. Kume, N. Takeda, and T. Oguma Sphingosine 1-phosphate causes airway hyper-reactivity by Rho-mediated myosin phosphatase inactivation J Pharmacol Exp Ther 320 2007 766 773
69. K. Budde, R.L. Schmouder, and R. Brunkhorst First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients J Am Soc Nephrol 13 2002 1073 1083
70. Gilenya Summary of Product Characteristics http://www.medicines.org.uk/emc/medicine/24443/SPC 2013 [Accessed December 4, 2013]
71. J. Tamargo, R. Caballero, and R. Gómez Pharmacology of cardiac potassium channels Cardiovasc Res 62 2004 9 33
72. + current in guinea-pig atrial myocytes by sphingosine-1-phosphate J Physiol 489 1995 701 707
73. + current diversity in mouse ventricular myocytes J Physiol 521 1999 587 599
74. J.P. DiMarco, P. O'Connor, and J.A. Cohen First-dose effects of fingolimod: Pooled safety data from three phase 3 studies Mult Scler Relat Disord 3 2014 629 638
75. M. Yamada The role of muscarinic K(+) channels in the negative chronotropic effect of a muscarinic agonist J Pharmacol Exp Ther 300 2002 681 687
76. P. Gergely, B. Nuesslein-Hildesheim, and D. Guerini The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate Br J Pharmacol 16 2012 1035 1047
77. J.B. Moberly, D.M. Ford, and H. Zahir Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: results from a 12-week, open-label pilot study in multiple sclerosis patients J Neuroimmunol 246 2012 100 107
78. D. Mazurais, P. Robert, and B. Gout Cell type-specific localization of human cardiac S1P receptors J Histochem Cytochem 50 2002 661 670
79. M.J. Lee, S. Thangada, and K.P. Claffey Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate Cell 99 1999 301 312
80. P.A. Singleton, S.M. Dudek, and S.F. Ma Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family J Biol Chem 281 2006 34381 34393
81. 1 antagonist in vivo Nat Chem Biol 2 2006 434 441
82. X. Peng, P.M. Hassoun, and S. Sammani Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury Am J Respir Crit Care Med 169 2004 1245 1251
83. Peripheral and Central Nervous System Drugs Advisory Committee Meeting Fingolimod (NDA 22-527) Background Package http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drudr/peripheralandcentralnervoussystemdrugsadvisorycommittee/ucm214670.pdf 2010 [Accessed December 4, 2013]
84. N. Bhagat, R.A. Grigorian, and A. Tutela Diabetic macular edema: pathogenesis and treatment Surv Ophthalmol 54 2009 1 32
85. M.A. Zarbin, L.M. Jampol, and R.D. Jager Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis Ophthalmology 120 2013 1432 1439
86. G. Comi Position and practical use of fingolimod in Europe Clin Exp Neuroimmunol 5 2014 19 33
87. US Food and Drug Administration FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod) http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm#data [Accessed June 6, 2014]
88. J. DiMarco, P. O'Connor, and J.A. Cohen Fingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three phase 3 studies Mult Scler 18 4 Suppl. 2012 55 277
89. R. Gold, G. Comi, and J. Palace Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study J Neurol 261 2 2014 267 276
90. B. Hughes, M. Cascione, and K. McCague Cardiac effects of fingolimod after first dose administration and therapy change in patients with multiple sclerosis Neurology 80 2013 [Meeting Abstracts 1:P01.170]
91. A. Laroni, D. Brogi, and V.B. Morra Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial BMC Neurol 14 2014 65
92. R. Schmouder, D. Serra, and Y. Wang FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects J Clin Pharmacol 46 2006 895 904
93. R. Bermel, R. Hashmonay, and X. Meng Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly treated with serotonin specific reuptake inhibitors Mult Scler 19 11 Suppl. 2013 74 558
94. B.A. Singer Initiating oral fingolimod treatment in patients with multiple sclerosis Ther Adv Neurol Disord 6 2013 269 275